Mirum stock gains on Q2 revenue, upgraded outlook

Mirum Pharmaceuticals rallied after strong Q2 revenue tied to LIVMARLI and its bile acid portfolio, expansion into new rare-disease patients, and an upgraded full-year outlook. Investors are awaiting the Sept. 26 FDA decision on zilurgisertib, and leadership was granted new stock options.